Previous 10 | Next 10 |
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET. The audio presentation will be webcast live and may be accessed via a link on the San...
Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q1 2020 Earnings Call May 11, 2020 , 5:00 p.m. ET Operator Continue reading
Sangamo Therapeutics, Inc. (SGMO) Q1 2020 Results Conference Call May 11, 2020 05:00 PM ET Company Participants McDavid Stilwell - SVP, Corporate Communication and IR Sandy Macrae - CEO Sung Lee - CFO Stephane Boissel - Head, Corporate Strategy Adrian Woolfson - Head, Researc...
Sangamo Therapeutics (NASDAQ: SGMO ): Q1 GAAP EPS of -$0.37 misses by $0.01 . Revenue of $13.08M (+62.1% Y/Y) misses by $9.65M . Cash and equivalents of $363.1M. Shares -4.8% . Press Release More news on: Sangamo Therapeutics, Inc., Earnings news and commentary, Healthcare sto...
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights. “I’m proud of how the Sangamo team has worked t...
May 8, 2020 FN Media Group Presents Financialmorningpost.com Market Commentary New York, NY – May 8, 2020 – The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic. The previously announced dat...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020. The press release will be followed by a conference call at 5:00 p.m. E...
You can't lump all clinical-stage biotechs together. Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO) , for example. The two biotechs are about as different as night and day. One thing that both Cara and Sangamo have in common, though, are promising ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12 th to May 15 th , 2020, in a virtual format. ...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...